Use of a Metabolic Syndrome Severity Z Score to Track Risk During Treatment of Prediabetes: An Analysis of the Diabetes Prevention Program

Mark D DeBoer, Stephanie L Filipp, Matthew J Gurka, Mark D DeBoer, Stephanie L Filipp, Matthew J Gurka

Abstract

Objective: We assessed whether changes in metabolic syndrome (MetS) severity during the treatment of prediabetes are associated with reduced risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD).

Research design and methods: We analyzed data from the Diabetes Prevention Program (DPP) for 2,476 adults in 1996-1999 with prediabetes randomized to receive treatment with lifestyle modification, metformin, or placebo for 2-3 years and followed through 2014 for T2DM and CVD outcomes. We calculated effect sizes from baseline in a MetS severity z score (MetS-Z) and the individual MetS components, and assessed relationships between 1-year effect size and incident T2DM and CVD using hazard ratios (HRs) and mediation analysis.

Results: Baseline MetS-Z and its components were associated with risk of incident T2DM and CVD. During year 1 of intervention, MetS-Z and its components decreased most with lifestyle modification, followed by treatment with metformin and placebo. Risk of T2DM within 1-5 years was most strongly associated with 1-year changes in MetS-Z and waist circumference (both HRs for a 1 SD increase = 1.80), whereas the risk of CVD was associated with a 1-year change in MetS-Z, glucose, and systolic blood pressure. In mediation analyses, the effect of lifestyle modification on T2DM risk was mediated by 1-year changes in MetS-Z, waist circumference, glucose, and triglycerides, whereas the effect of metformin was mediated by MetS-Z and glucose.

Conclusions: Changes in these risk indicators of MetS severity during intervention in the DPP reflect altered disease risk and may help in tracking earlier responses to treatment and in motivating patients.

Trial registration: ClinicalTrials.gov NCT00004992 NCT00038727.

© 2018 by the American Diabetes Association.

Figures

Figure 1
Figure 1
Changes in MetS-Z and the individual MetS components over 3 years of intervention. Mean effect sizes (i.e., the change from baseline, divided by the SD at baseline) ±95% CIs for MetS-Z, WC, fasting glucose, triglycerides, HDL cholesterol, and SBP during intervention with lifestyle modification, and treatment with metformin and placebo. The mean absolute effects are provided in Supplementary Table 1.

References

    1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. .; American Heart Association Statistics Committee and Stroke Statistics Subcommittee . Heart disease and stroke statistics—2017 update: a report from the American Heart Association [published correction appears in Circulation 2017;135:e646; 136:e196]. Circulation 2017;135:e146–e603
    1. Centers for Disease Control and Prevention National Diabetes Statistics Report, 2017. Atlanta, GA, Centers for Disease Control and Prevention, 2017
    1. American Diabetes Association 5. Prevention or delay of type 2 diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018;41(Suppl. 1):S51–S54
    1. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 2014;371:2237–2238
    1. DeBoer MD. Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions. Nutrition 2013;29:379–386
    1. Grundy SM, Cleeman JI, Daniels SR, et al. .; American Heart Association; National Heart, Lung, and Blood Institute . Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–2752
    1. Goodman E, Daniels SR, Meigs JB, Dolan LM. Instability in the diagnosis of metabolic syndrome in adolescents. Circulation 2007;115:2316–2322
    1. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes . The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289–2304
    1. Mozaffarian D, Kamineni A, Prineas RJ, Siscovick DS. Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med 2008;168:969–978
    1. Gurka MJ, Lilly CL, Oliver MN, DeBoer MD. An examination of sex and racial/ethnic differences in the metabolic syndrome among adults: a confirmatory factor analysis and a resulting continuous severity score. Metabolism 2014;63:218–225
    1. Gurka MJ, Golden SH, Musani SK, et al. . Independent associations between a metabolic syndrome severity score and future diabetes by sex and race: the Atherosclerosis Risk In Communities Study and Jackson Heart Study. Diabetologia 2017;60:1261–1270
    1. DeBoer MD, Gurka MJ, Woo JG, Morrison JA. Severity of the metabolic syndrome as a predictor of type 2 diabetes between childhood and adulthood: the Princeton Lipid Research Cohort Study. Diabetologia 2015;58:2745–2752
    1. DeBoer MD, Gurka MJ, Morrison JA, Woo JG. Inter-relationships between the severity of metabolic syndrome, insulin and adiponectin and their relationship to future type 2 diabetes and cardiovascular disease. Int J Obes 2016;40:1353–1359
    1. DeBoer MD, Gurka MJ, Woo JG, Morrison JA. Severity of metabolic syndrome as a predictor of cardiovascular disease between childhood and adulthood: the Princeton Lipid Research Cohort Study. J Am Coll Cardiol 2015;66:755–757
    1. DeBoer MD, Gurka MJ, Golden SH, et al. . Independent associations between metabolic syndrome severity and future coronary heart disease by sex and race. J Am Coll Cardiol 2017;69:1204–1205
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. .; Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
    1. The Diabetes Prevention Program Research Group The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes [published correction appears in Diabetes Care 1999;22:1389]. Diabetes Care 1999;22:623–634
    1. Ratner R, Goldberg R, Haffner S, et al. .; Diabetes Prevention Program Research Group . Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 2005;28:888–894
    1. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004;57:1096–1103
    1. Gurka MJ, Ice CL, Sun SS, Deboer MD. A confirmatory factor analysis of the metabolic syndrome in adolescents: an examination of sex and racial/ethnic differences. Cardiovasc Diabetol 2012;11:128.
    1. Sumner AE, Cowie CC. Ethnic differences in the ability of triglyceride levels to identify insulin resistance. Atherosclerosis 2008;196:696–703
    1. DeBoer MD, Gurka MJ, Sumner AE. Diagnosis of the metabolic syndrome is associated with disproportionately high levels of high-sensitivity C-reactive protein in non-Hispanic black adolescents: an analysis of NHANES 1999-2008. Diabetes Care 2011;34:734–740
    1. DeBoer MD, Dong L, Gurka MJ. Racial/ethnic and sex differences in the ability of metabolic syndrome criteria to predict elevations in fasting insulin levels in adolescents. J Pediatr 2011;159:975–981.e3
    1. VanderWeele TJ. A unification of mediation and interaction: a 4-way decomposition. Epidemiology 2014;25:749–761
    1. Hafeman DM, Schwartz S. Opening the Black Box: a motivation for the assessment of mediation. Int J Epidemiol 2009;38:838–845
    1. Hafeman DM. “Proportion explained”: a causal interpretation for standard measures of indirect effect? Am J Epidemiol 2009;170:1443–1448
    1. Stone NJ, Robinson JG, Lichtenstein AH, et al. .; 2013 ACC/AHA Cholesterol Guideline Panel . Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med 2014;160:339–343
    1. Lloyd-Jones DM, Huffman MD, Karmali KN, et al. . Estimating longitudinal risks and benefits from cardiovascular preventive therapies among medicare patients: the Million Hearts Longitudinal ASCVD Risk Assessment Tool: a special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2017;69:1617–1636
    1. Scheitel MR, Kessler ME, Shellum JL, et al. . Effect of a novel clinical decision support tool on the efficiency and accuracy of treatment recommendations for cholesterol management. Appl Clin Inform 2017;8:124–136
    1. Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia 2009;52:2001–2014
    1. Golden SH, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the Atherosclerosis Risk in Communities Study. Diabetes 2002;51:3069–3076
    1. Gurka MJ, Guo Y, Filipp SL, DeBoer MD. Metabolic syndrome severity is significantly associated with future coronary heart disease in type 2 diabetes. Cardiovasc Diabetol 2018;17:17.
    1. Gurka MJ, Filipp SL, Pearson TA, DeBoer MD. Assessing baseline and temporal changes in cardiometabolic risk using metabolic syndrome severity and common risk scores. J Am Heart Assoc 2018;7:e009754
    1. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881–887
    1. Bauduceau B, Vachey E, Mayaudon H, et al. . Should we have more definitions of metabolic syndrome or simply take waist measurement? Diabetes Metab 2007;33:333–339
    1. Agency for Healthcare Research and Quality 2010 National Healthcare Quality Report; AHRQ Publication No. 11-0004. Rockville, MD, Agency for Healthcare Research and Quality, 2010
    1. Diabetes Prevention Program Research Group Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 2015;3:866–875
    1. Carroll C, Naylor E, Marsden P, Dornan T. How do people with type 2 diabetes perceive and respond to cardiovascular risk? Diabet Med 2003;20:355–360
    1. Lopez-Gonzalez AA, Aguilo A, Frontera M, et al. . Effectiveness of the Heart Age tool for improving modifiable cardiovascular risk factors in a Southern European population: a randomized trial. Eur J Prev Cardiol 2015;22:389–396
    1. Knowler WC, Fowler SE, Hamman RF, et al. .; Diabetes Prevention Program Research Group . 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study [published correction appears in Lancet 2009;374:2054]. Lancet 2009;374:1677–1686

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다